Palla Pharma Ltd
ASX:PAL
Palla Pharma Ltd
ASX:PAL
Price:
0.295 AUD
Market Closed
Updated:
Apr 30, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of PAL.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PAL
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
PAL Competitors Multiples
Palla Pharma Ltd Competitors
Palla Pharma Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Palla Pharma Ltd
ASX:PAL
|
47.8m AUD | 2.8 | -0.8 | -2 | -2 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
223.1B USD | 5.2 | 37.2 | 23 | 33.7 | |
| US |
|
Danaher Corp
NYSE:DHR
|
182.8B USD | 4.2 | 22.7 | 16.5 | 20.3 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
42.7B USD | 2.9 | 31.5 | 17 | 26.3 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
37.1B CHF | 5.5 | 56 | 19.5 | 28.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
40.9B USD | 6.1 | 33.1 | 26.5 | 31.8 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.6T KRW | 15 | 64.8 | 34.2 | 49.2 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27B USD | 7.1 | 34.3 | 23.9 | 26.6 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
26B USD | 8.8 | 43.9 | 30 | 35.8 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
25.1B USD | 3.1 | 41 | 17.4 | 27.1 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.1B EUR | 7 | 74.6 | 32.3 | 53 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
